Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 2Genitourinary 2Dermatologic 2Breast 2Gynecologic 1

Conditions

Melanoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Ovarian Neoplasms 1Neoplasms 1

Interventions

pembrolizumab 19Nivolumab 16Cyclophosphamide 9Specimen Handling 7Ipilimumab 7atezolizumab 6fludarabine 5Magnetic Resonance Spectroscopy 5durvalumab 3avelumab 3X-Rays 3Biopsy 3ulixertinib 2sargramostim 2poly ICLC 2lenvatinib 2epacadostat 2enzalutamide 2cemiplimab 2cabozantinib 2budigalimab 2aldesleukin 2Trastuzumab 2Sirolimus 2Paclitaxel 2Melphalan 2Interleukin-2 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Docetaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × ARQ 197 × Dermatologic × Clear all
NCT01178411 2021-03-10

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Completed
60 enrolled 11 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms

NCT00827177 2014-01-24

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
87 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡